Hyperkalemia in hypertensive patients undergoing regular hemodialysis during enalapril and fosinopril therapy

Dimković, Nada; Djordjević, Tanja; Popović, Jovan; Dimković, Siniša; Tirmenštajn-Janković, Biserka; Zivanović, M; Bobanović-Hasković, Jasminka

doi:10.2298/sarh0602044d

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Long term treatment with (ACEI) angiotensin converting enzyme inhibitors motivate significant regression of left ventricular hypertrophy in uremic patients. 15 Therefore left ventricular hypertrophy is a dynamic cardiovascular risk factor for increased morbidity and mortality in hemodialysis patients, its early detection and regression of left ventricular hypertrophy will contribute to reduction in cardiovascular mortality in uremic population.…”

Section: Introductionmentioning

confidence: 99%

Left Ventricular Hypertrophy

Das

Ansari

Kumar

et al. 2015

TPMJ

View full text Add to dashboard Cite

Cardiovascular system diseases are playing the outstanding role in the cause ofmorbidity and mortality in dialysis patients. Left ventricular hypertrophy is one of the universalstructural abnormalities in patients on regular dialysis. Objective: The target of the study wasto search out the frequency of left ventricular hypertrophy in end stage renal disease patientson maintenance hemodialysis. Study design: Single center case-series study. Setting:Department of Nephro-Urology, Liaquat University of Medical & Health Sciences Jamshoro.Period: Begin from 1st March, 2013 to 30th August 2013. Results: Total numbers of patientswere seventy three. Thirty three patients were male and 40 were female. Mean age of thepatients was 44.19 years. High blood pressure was the most typical cause of nephropathy thatis as certain in twenty 9(39.7%) cases pursue by Diabetes and Chronic Glomerulonephritis intwenty (27.4%) in each, renal stone in four (5.5%), unresolved acute renal failure four(5.5%)and Chronic Tubulointerstitial nephritis in two(2.7%) patients. Left ventricular hypertrophy wasascertained in nineteen (26%) patients. Conclusion: Our study concedes the high frequency ofleft ventricular hypertrophy in dialysis patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Left Ventricular Hypertrophy

Das

Ansari

Kumar

et al. 2015

TPMJ

View full text Add to dashboard Cite

show abstract

“…15 Therefore left ventricular hypertrophy is a dynamic cardiovascular risk factor for increased morbidity and mortality in hemodialysis patients, its early detection and regression of left ventricular hypertrophy will contribute to reduction in cardiovascular mortality in uremic population.…”

mentioning

confidence: 99%

Left Ventricular Hypertrophy; Haemodialysis Patients

Das¹,

Ansari²,

Kumar³

et al. 2015

TPMJ

View full text Add to dashboard Cite

ABSTRACT… Cardiovascular system diseases are playing the outstanding role in the cause of morbidity and mortality in dialysis patients. Left ventricular hypertrophy is one of the universal structural abnormalities in patients on regular dialysis. Objective: The target of the study was to search out the frequency of left ventricular hypertrophy in end stage renal disease patients on maintenance hemodialysis. Study design: Single center case-series study. Setting: Department of Nephro-Urology, Liaquat University of Medical & Health Sciences Jamshoro. Period: Begin from 1 st March, 2013 to 30 th August 2013. Results: Total numbers of patients were seventy three. Thirty three patients were male and 40 were female. Mean age of the patients was 44.19 years. High blood pressure was the most typical cause of nephropathy that is as certain in twenty 9(39.7%) cases pursue by Diabetes and Chronic Glomerulonephritis in twenty (27.4%) in each, renal stone in four (5.5%), unresolved acute renal failure four(5.5%) and Chronic Tubulointerstitial nephritis in two(2.7%) patients. Left ventricular hypertrophy was ascertained in nineteen (26%) patients. Conclusion: Our study concedes the high frequency of left ventricular hypertrophy in dialysis patients.

show abstract

Renoprotective effect of calcium channel blockers

Dimković

2009

Srp Arh Celok Lek

View full text Add to dashboard Cite

The advancing chronic renal failure is at most the consequence of secondary haemodynamic and metabolic factors as intraglomerular hypertension and glomerular hypertrophy. Although tight blood pressure control is the major preventive mechanism for progressive renal failure, ACE inhibitors and angiotensin receptor blockers have some other renoprotective mechanisms beyond the blood pressure control. That is why these two groups of antihypertensive drugs traditionally have advantages in treating renal patients especially those with proteinuria over 400-1000 mg/day. Even if earlier experimental studies have shown renoprotective effect of calcium channel blockers, later clinical studies did not prove that calcium channel blockers have any advantages in renal protection over ACE inhibitors given as monotherapy or in combination with ACE inhibitors. It was explained by action of calcium channel blockers on afferent but not on efferent glomerular arterioles; a well known mechanism that leads to intraglomerular hypertension. New generations of dihydropiridine calcium channel blockers can dilate even efferent arterioles not causing unfavorable haemodynamic disturbances. This finding was confirmed in clinical studies which showed that renoprotection established by calcium channel blockers was not inferior to that of ACE inhibitors and that calcium channel blockers and ACE inhibitors have additive effect on renoprotection. Newer generation of dihydropiridine calcium channel blockers seem to offer more therapeutic possibilities in renoprotection by their dual action on afferent and efferent glomerular arterioles and, possibly by other effects beyond the blood pressure control.

show abstract

Hyperkalemia in hypertensive patients undergoing regular hemodialysis during enalapril and fosinopril therapy

Cited by 3 publications

References 7 publications

Left Ventricular Hypertrophy

Left Ventricular Hypertrophy

Left Ventricular Hypertrophy; Haemodialysis Patients

Renoprotective effect of calcium channel blockers

Contact Info

Product

Resources

About